Post-Viral Fatigue Syndrome
Conditions
Interventions
This is a double-blind and crossover study, controlled with placebo. An external researcher carried out the randomization and labeling of the bottles in A and B according to their distribution, so tha
D03.383.725.762.740
Sponsors
Universidade Federal Fluminense
Universidade Federal Fluminense
Eligibility
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Individuals with a recent history of SARS Cov2 infection, confirmed by positive PCR; age between 18 and 65 years; patients who maintain permanent symptoms, mainly fatigue, after 4 weeks of the onset of the illness
Exclusion criteria
Exclusion criteria: Individuals with some type of motor or mental disability that prevents the performance of the proposed tests; pregnant women; subjects with known hypersensitivity to pyridostigmine; individuals with conditions that contraindicate the use of pyridostigmine, such as glaucoma, asthma and urinary obstruction; patients with heart rhythm different from sinus rhythm, with atrial fibrillation, frequent ventricular and/or supraventricular ectopy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find an improvement in the fatigue of these patients, reflected in the improvement of the quality of life, being demonstrated through the answers of the questionnaires of fatigue and quality of life, besides an improvement of the performance in the ergospirometry test. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to describe the autonomic changes in patients and demonstrate their improvement after the use of pyridostigmine bromide, through the performance of autonomic tests, such as breath test, handgrip, valsalva maneuver and active orthostatism. | — |
Countries
Brazil
Contacts
Public ContactJoelma Rocha
Universidade Federal Fluminense
Outcome results
None listed